Qiagen NV
QGEN
View Detailed Chart
47.190USD
-0.760-1.58%
Close 10/29, 16:00（ET）Quotes delayed by 15 min
10.23BMarket Cap
27.40P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-1.58%
5 Days
-2.90%
1 Month
+7.40%
6 Months
+10.70%
Year to Date
+5.99%
1 Year
+12.83%
View Detailed Chart
TradingKey Stock Score of Qiagen NV
Currency: USD Updated: 2025-10-28Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Qiagen NV's Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
18
analysts
Buy
Current Rating
51.073
Target Price
+5.52%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Qiagen NV Highlights
StrengthsRisks
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
Fairly Valued
The company’s latest PE is 27.88, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 196.38M shares, decreasing 6.05% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 5.37K shares of this stock.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Qiagen NV Info
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
Ticker SymbolQGEN
CompanyQiagen NV
CEOMr. Thierry Bernard
Websitehttps://www.qiagen.com/
Related Instruments
-1.72%
-0.14%
-12.52%
+1.00%
-0.63%
-1.60%
+0.70%
+2.60%
-2.96%
-6.63%
-0.10%
-0.88%
-2.30%
-0.26%
-1.61%
-3.00%
-1.77%
-4.89%
-4.14%
-3.88%Popular Symbols
